|
Delayed
Nasdaq Stockholm
12:00:03 30/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.3750 SEK | -0.13% |
|
-11.45% | -54.76% |
| 10-21 | Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study | MT |
| 10-21 | Alzinova selects seven U.S. trial sites ahead of phase IIa study | FW |
Company Valuation: Alzinova AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 101.6 | 89.8 | 135.2 | 308.5 | 86.48 | 118.7 | - | - |
| Change | - | -11.61% | 50.5% | 128.27% | -71.97% | 37.23% | - | - |
| Enterprise Value (EV) 1 | 73.56 | 89.8 | 113.1 | 293 | 102 | 109.7 | 114.7 | 118.7 |
| Change | - | 22.08% | 25.97% | 159.02% | -65.2% | 7.55% | 4.56% | 3.49% |
| P/E | -13.4x | - | -7.4x | -11.2x | -3.07x | -2.68x | -1.39x | -1.39x |
| PBR | - | - | - | - | 0.71x | 0.66x | 0.58x | 0.51x |
| PEG | - | - | - | 0.5x | 0.2x | 0.1x | -0x | - |
| Capitalization / Revenue | - | - | 501x | - | - | 3.79x | - | 12.8x |
| EV / Revenue | - | - | 419x | - | - | 3.5x | - | 12.8x |
| EV / EBITDA | -9.78x | - | - | -14.4x | -3.98x | -56.2x | -1.08x | -1.12x |
| EV / EBIT | -9.78x | - | -6.85x | -14.4x | -3.98x | -56.2x | -1.08x | -1.12x |
| EV / FCF | -2.71x | - | -3.25x | -7.91x | -2.58x | -1.52x | -1.01x | -1.04x |
| FCF Yield | -36.9% | - | -30.8% | -12.6% | -38.8% | -65.6% | -99.4% | -96.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.48 | - | -0.41 | -0.31 | -0.27 | -0.14 | -0.27 | -0.27 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | 0.27 | - | - | 31.35 | - | 9.25 |
| EBITDA 1 | -7.519 | - | - | -20.38 | -25.6 | -1.95 | -106 | -106 |
| EBIT 1 | -7.519 | - | -16.52 | -20.38 | -25.6 | -1.95 | -106 | -106 |
| Net income 1 | -7.552 | -13.09 | -16.48 | -20.55 | -26.27 | 1.55 | -84 | -84 |
| Net Debt 1 | -28.04 | - | -22.03 | -15.5 | 15.5 | -9 | -4 | - |
| Reference price 2 | 6.4400 | 2.7700 | 3.0350 | 3.4600 | 0.8290 | 0.3755 | 0.3755 | 0.3755 |
| Nbr of stocks (in thousands) | 15,776 | 32,419 | 44,531 | 89,165 | 104,324 | 316,059 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 28/02/24 | 27/02/25 | 25/03/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.68x | 3.5x | -56.25x | - | 12.04M | |
| 16.97x | 6.42x | 12.3x | 1.76% | 64.38B | |
| 30.03x | 8.21x | 26.91x | 0.04% | 56.16B | |
| 37.32x | 6.62x | 19.78x | 0.87% | 54.16B | |
| 35.94x | 3.4x | 14.66x | -.--% | 45.33B | |
| 49.01x | 5.65x | 30.93x | -.--% | 42.25B | |
| -19.75x | 191.25x | -21.04x | -.--% | 40.78B | |
| 46.05x | 8.16x | 27.33x | -.--% | 33.8B | |
| 31.61x | 8.04x | 20.91x | 0.41% | 32.25B | |
| 27.18x | 5.72x | 14.84x | -.--% | 23.57B | |
| Average | 25.17x | 24.70x | 9.04x | 0.34% | 39.27B | |
| Weighted average by Cap. | 27.79x | 25.71x | 16.39x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALZ Stock
- Valuation Alzinova AB
Select your edition
All financial news and data tailored to specific country editions
